Background: Vascular access failure is a common cause of morbidity in patients with end-stage renal failure on hemodialysis (HD). Activation of the coagulation system and formation of a thrombus play important roles in recurrent arteriovenous fistula/graft (AVFG) failure. Thrombin in complex with thrombomodulin (TM) activates the anticoagulant protein C and creates activated protein C (APC), which is subsequently inactivated by the protein C inhibitor (PCI). The plasma concentration of the complex between APC and PCI (P-APC-PCI complex) is increased in hypercoagulable states and is therefore a sensitive indicator of the degree of activation of blood coagulation. Methods: Thirty-five HD patients dialyzed through a functioning AVFG were studied. The period of patency of AVFGs was recorded. Blood was drawn before and after the HD session for the analysis of the APC-PCI complex, soluble TM concentration and activity, von Willebrand factor antigen and homocysteine. Results: Patients with frequent AVFG failures (n = 8) had a significantly lower level of P-APC-PCI complex (median 0.09 µg/l) than those with less frequent AVFG failures (median 0.18 µg/l; n = 27; p = 0.04). No other significant differences were found between the groups. Conclusion: Thus, a low level of P-APC-PCI complex may be associated with an increased risk of AVFG failure in HD patients. Further prospective studies are needed to confirm these results and to evaluate the possibility of prophylactic measures.

Keywords:
Activated protein C-protein C inhibitor complex, Vascular access failure, Hemodialysis patients
1.
Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA: Hemodialysis vascular access morbidity in the United States. Kidney Int 1993;43:1091–1096.
2.
Goldwasser P, Avram MM, Collier JT, Michel MA, Gusik SA, Mittman N: Correlates of vascular access occlusion in hemodialysis. Am J Kidney Dis 1994;24:785– 794.
3.
Palder SB, Kirkman RL, Whittemore AD, Hakim RM, Lazarus JM, Tilney NL: Vascular access for hemodialysis. Patency rates and results of revision. Ann Surg 1985;202:235–239.
4.
Dahlback B: Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 2005;257:209–223.
5.
Rustom R, Leggat H, Tomura HR, Hay CR, Bone JM: Plasma thrombomodulin in renal disease: effects of renal function and proteinuria. Clin Nephrol 1998;50:337–341.
6.
Nakayama M, Yamada K, Yamamoto Y, Yokoyama K, Nakano H, Kubo H, et al: Vascular endothelial dysfunction in patients on regular dialysis treatment. Clin Nephrol 1994;42:117–120.
7.
Borawski J, Naumnik B, Pawlak K, Mysliwiec M: Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients. Nephrol Dial Transplant 2001;16:787–792.
8.
Borawski J, Naumnik B, Mysliwiec M: Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy. Clin Appl Thromb Hemost 2002;8:359–367.
9.
Kushiya F, Wada H, Sakakura M, Mori Y, Gabazza EC, Nishikawa M, et al: Effects of lipid abnormalities on arteriosclerosis and hemostatic markers in patients under hemodialysis. Clin Appl Thromb Hemost 2003;9:203–210.
10.
Pawlak K, Naumnik B, Brzosko S, Pawlak D, Mysliwiec M: Oxidative stress – a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients. Am J Nephrol 2004;24:154–161.
11.
Taniguchi Y, Yorioka N, Oda H, Masaki T, Usui K, Harada S, et al: Plasma thrombomodulin: usefulness as a blood access failure marker in hemodialysis patients. Nephron 1996;73:91–93.
12.
Taniguchi Y, Yorioka N, Yamashita K, Masaki T, Yamakido M: Transforming growth factor-beta1 may be involved in shunt obstruction in patients on chronic hemodialysis. Nephron 1999;81:102–105.
13.
Strandberg K, Stenflo J, Nilsson C, Svensson PJ: APC-PCI complex concentration is higher in patients with previous venous thromboembolism with Factor V Leiden. J Thromb Haemost 2005;3:2578–2580.
14.
Bhiladvala P, Strandberg K, Stenflo J, Holm J: Early identification of acute myocardial infarction by activated protein C-protein C inhibitor complex. Thromb Res 2006;118:213–219.
15.
Navarro S, Ricart JM, Medina P, Vaya A, Villa P, Todoli J, et al: Activated protein C levels in Behcet’s disease and risk of venous thrombosis. Br J Haematol 2004;126:550–556.
16.
Monnerat C, Hayoz D: Homocysteine and venous thromboembolism (in French). Schweiz Med Wochenschr 1997;127:1489–1496.
17.
Manns BJ, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas NW: Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int 1999;55:315–320.
18.
Shemin D, Lapane KL, Bausserman L, Kanaan E, Kahn S, Dworkin L, et al: Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol 1999;10:1095–1099.
19.
Ducloux D, Pascal B, Jamali M, Gibey R, Chalopin JM: Is hyperhomocysteinaemia a risk factor for recurrent vascular access thrombosis in haemodialysis patients? Nephrol Dial Transplant 1997;12:2037–2038.
20.
Mezzano D, Pais EO, Aranda E, Panes O, Downey P, Ortiz M, et al: Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001;60:1844–1850.
21.
Ohlin AK, Morser J, Ohlin H: Soluble thrombomodulin antigen in plasma is increased in patients with acute myocardial infarction treated with thrombolytic therapy. Thromb Res 1996;82:313–322.
22.
Ohlin AK, Larsson K, Hansson M: Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma. J Thromb Haemost 2005;3:976–982.
23.
Strandberg K, Kjellberg M, Knebel R, Lilja H, Stenflo J: A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: use of a catcher antibody specific for the complexed/cleaved form of the inhibitor. Thromb Haemost 2001;86:604–610.
24.
Inoue A, Wada H, Takagi M, Yamamuro M, Mukai K, Nakasaki T, et al: Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis. Clin Appl Thromb Hemost 2000;6:100–103.
25.
Knoll GA, Wells PS, Young D, Perkins SL, Pilkey RM, Clinch JJ, et al: Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol 2005;16:1108–1114.
26.
Woods JD, Turenne MN, Strawderman RL, Young EW, Hirth RA, Port FK, et al: Vascular access survival among incident hemodialysis patients in the United States. Am J Kidney Dis 1997;30:50–57.
27.
Song IS, Yang WS, Kim SB, Lee JH, Kwon TW, Park JS: Association of plasma fibrinogen concentration with vascular access failure in hemodialysis patients. Nephrol Dial Transplant 1999;14:137–141.
28.
Suzuki K: Activated protein C inhibitor. Semin Thromb Hemost 1984;10:154–161.
29.
Pratt CW, Church FC: Heparin binding to protein C inhibitor. J Biol Chem 1992;267:8789–8794.
30.
Watanabe R, Wada H, Sakakura M, Mori Y, Nakasaki T, Okugawa Y, et al: Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states. Am J Hematol 2000;65:35–40.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.